Information Provided By:
Fly News Breaks for December 5, 2016
INCY
Dec 5, 2016 | 07:56 EDT
RBC Capital analyst Simos Simeonidis believes that data for Incyte's INCB39110 in GvHD was "promising." The analyst notes that patients who received INCB39110 as a first-line treatment had an 83.3% overall response rate, while the drug was well-tolerated by all patients. He keeps an Outperform rating on the shares.
News For INCY From the Last 2 Days
There are no results for your query INCY